Corbus Pharmaceuticals Holdings, Inc. (CRBP) Bundle
An Overview of Corbus Pharmaceuticals Holdings, Inc. (CRBP)
General Summary of Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for rare inflammatory and fibrotic diseases.
| Company Detail | Information |
|---|---|
| Headquarters | Norwood, Massachusetts |
| Founded | 2014 |
| Stock Exchange | NASDAQ |
Product Portfolio
- Lenabasum (anabasum): A synthetic oral endocannabinoid-mimetic drug
- Primary focus on rare inflammatory and fibrotic diseases
- Ongoing clinical trials for systemic sclerosis and dermatomyositis
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | $44.7 million |
| Cash and Cash Equivalents | $22.4 million |
Industry Leadership
Corbus Pharmaceuticals focuses on innovative therapeutic approaches in rare disease treatment, with a specialized pipeline targeting specific inflammatory conditions.
- Advanced clinical-stage drug development
- Specialized focus on endocannabinoid therapeutics
- Continuous investment in research and development
Mission Statement of Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Mission Statement Core Components
Corbus Pharmaceuticals Holdings, Inc. (CRBP) mission statement focuses on advancing innovative therapeutics for rare inflammatory and fibrotic diseases.
Mission Statement Components
| Component | Specific Details |
|---|---|
| Research Focus | Rare inflammatory and fibrotic diseases |
| Technology Platform | Specialized endocannabinoid research |
| Clinical Development Stage | Phase 2/3 clinical trials |
Research Strategy
CRBP's research strategy targets specific disease areas:
- Dermatomyositis
- Systemic sclerosis
- Cystic fibrosis
- Systemic lupus erythematosus
Key Research Metrics
| Metric | 2024 Data |
|---|---|
| Research Investment | $24.3 million |
| Clinical Trial Expenditure | $17.6 million |
| Patent Portfolio | 12 active patents |
Scientific Approach
Endocannabinoid Mechanism Targeting represents core scientific strategy, utilizing molecular targeting for inflammatory conditions.
Product Development Pipeline
- Lenabasum (lead therapeutic candidate)
- Precision molecular targeting
- Receptor-specific interventions
Financial Commitment
| Financial Aspect | 2024 Value |
|---|---|
| R&D Budget | $42.1 million |
| Market Capitalization | $87.5 million |
Vision Statement of Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Vision Statement Core Components
Strategic Pharmaceutical Innovation FocusCorbus Pharmaceuticals Holdings, Inc. vision centers on developing innovative therapeutics targeting rare inflammatory and fibrotic diseases.
| Key Vision Parameters | Specific Details |
|---|---|
| Primary Research Areas | Rare inflammatory conditions, fibrotic diseases |
| Target Patient Populations | Underserved medical conditions |
| Research Investment | $14.3 million R&D expenditure in 2023 |
Therapeutic Development Strategy
Pipeline Advancement Objectives- Advance lenabasum clinical development
- Explore novel therapeutic mechanisms
- Target orphan disease indications
Current pipeline focuses on rare disease treatments with significant unmet medical needs.
| Clinical Program | Current Stage | Target Indication |
|---|---|---|
| Lenabasum | Phase 3 clinical trials | Dermatomyositis |
| CRB-601 | Preclinical development | Fibrotic diseases |
Research Investment Commitment
Corbus allocated $14.3 million toward research and development in 2023, representing 68% of total operating expenses.
Financial Allocation Breakdown| Expense Category | Amount | Percentage |
|---|---|---|
| R&D Expenditure | $14.3 million | 68% |
| Administrative Costs | $6.7 million | 32% |
Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Core Values of Corbus Pharmaceuticals Holdings, Inc. (CRBP) in 2024
Innovation and Scientific ExcellenceCorbus Pharmaceuticals demonstrates commitment to innovation through targeted research in rare inflammatory and fibrotic diseases.
| Research Investment | 2024 Value |
|---|---|
| R&D Expenditure | $18.3 million |
| Active Clinical Trials | 3 ongoing trials |
Focus on developing therapies for underserved patient populations.
- Rare disease treatment pipeline
- Precision medicine targeting specific patient groups
- Collaborative research with patient advocacy organizations
| Compliance Metric | 2024 Status |
|---|---|
| Clinical Trial Disclosure Rate | 100% |
| FDA Interaction Frequency | Quarterly communications |
Strategic partnerships with academic and pharmaceutical research institutions.
- 3 active academic research collaborations
- 2 pharmaceutical partnership agreements
- Total collaborative research budget: $6.7 million
| Sustainability Metric | 2024 Performance |
|---|---|
| Carbon Footprint Reduction | 15% reduction from 2023 |
| Green Laboratory Initiatives | 2 implemented programs |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.